急性心肌梗死后幽门螺杆菌筛查:HELP-MI SWEDEHEART 整群随机交叉试验
该研究为全国性、开放标签、两周期两序列整群随机交叉临床试验,纳入瑞典35家医院(18个集群)的18466例急性心肌梗死患者,随机比较常规幽门螺杆菌筛查(尿素呼气试验)与常规护理。筛查期9245例,非筛查期9221例。中位随访1.9年,主要终点上消化道出血在筛查组299例(发生率16.8/1000人年,3年累积风险4.1%),常规护理组336例(19.2/1000人年,4.6%),RR 0.90(95%CI 0.77-1.05,P=0.18),差异未达统计学显著。预设非多重校正亚组分析显示异质性效应:无贫血RR 0.98(0.80-1.21),轻度贫血RR 0.64(0.42-0.98),中重度贫血RR 0.44(0.23-0.87),交互P=0.03。结论认为常规筛查未显著降低上消化道出血风险。
要点
- 在未选择的急性心肌梗死患者中,常规幽门螺杆菌筛查未显著降低上消化道出血风险:筛查组299例 vs 常规护理组336例,RR 0.90(95%CI 0.77-1.05,P=0.18)。
- 筛查期仅70%(6480例)实际接受检测,其中23.6%(1532例)幽门螺杆菌阳性。
- 预设非多重校正亚组分析提示异质性效应:中重度贫血患者RR 0.44(95%CI 0.23-0.87),轻度贫血RR 0.64(0.42-0.98),无贫血RR 0.98(0.80-1.21),交互P=0.03。
- 两组入院时质子泵抑制剂使用率均为24.7%(筛查期2284例,非筛查期2275例)。
- 主要终点3年累积风险筛查组4.1% vs 常规护理组4.6%,发生率16.8 vs 19.2/1000人年。
适用人群与场景
- 瑞典35家医院(18个集群)收治的急性心肌梗死住院患者,中位年龄71岁(IQR 61-79),男性13138例(71%)。
- 研究人群为未选择的急性心肌梗死患者,筛查期9245例,非筛查期9221例。
处置流程与药物剂量
- 筛查期在标准护理基础上常规加用尿素呼气试验筛查幽门螺杆菌,覆盖所有急性心肌梗死住院患者。
研究设计与关键结果
- 研究类型:全国性、开放标签、两周期两序列整群随机交叉临床试验,使用临床注册登记定义研究人群并收集数据,与国家瑞典健康数据注册登记合并。
- 样本量与设置:18466例急性心肌梗死患者,来自35家瑞典医院(18个集群),2021年11月17日至2024年1月17日入组,随访至2025年1月17日。
- 干预与对照:筛查期常规加用尿素呼气试验筛查幽门螺杆菌 vs 常规护理期,两序列交叉,洗脱期2个月。
- 主要终点:上消化道出血,筛查组299例(发生率16.8/1000人年,3年累积风险4.1%)vs 常规护理组336例(19.2/1000人年,4.6%),RR 0.90(95%CI 0.77-1.05,P=0.18),差异未达统计学显著。
- 亚组分析(预设非多重校正):无贫血RR 0.98(95%CI 0.80-1.21),轻度贫血RR 0.64(0.42-0.98),中重度贫血RR 0.44(0.23-0.87),交互P=0.03。
- 筛查执行情况:筛查期6480例(70%)接受检测,其中1532例(23.6%)幽门螺杆菌阳性。
- 质子泵抑制剂使用:入院时筛查期2284例(24.7%)vs 非筛查期2275例(24.7%)。
证据类型、等级与局限
- 证据类型:整群随机交叉临床试验(RCT)。
- 试验注册:ClinicalTrials.gov NCT05024864。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在未选择的急性心肌梗死患者中,常规幽门螺杆菌筛查未显著降低上消化道出血风险,不支持对该人群常规筛查。
- 预设非多重校正亚组分析提示中重度贫血患者可能获益(RR 0.44,95%CI 0.23-0.87),但该分析为非多重校正,需进一步研究验证。
- 筛查期仅70%患者实际接受检测,可能影响干预效果的充分性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Upper gastrointestinal bleeding is common after myocardial infarction.
OBJECTIVE: To determine whether routine screening for Helicobacter pylori infection during hospitalization for myocardial infarction reduces bleeding events and improves clinical outcomes.
DESIGN, SETTING, AND PARTICIPANTS: A nationwide, open-label, 2-period, 2-sequence, cluster randomized, crossover clinical trial using a clinical registry for study population definition and data collection merged with national Swedish health data registries. From November 17, 2021, through January 17, 2024, thirty-five Swedish hospitals grouped into 18 clusters were randomized to a sequence of 1 year with routine H pylori screening of all patients with acute myocardial infarction followed by a washout period of 2 months before crossing over to 1 year with usual care or vice versa. Patients were followed up until January 17, 2025.
INTERVENTION: Routine addition of H pylori screening by urea breath test to standard care in all patients hospitalized for myocardial infarction during the screening periods.
MAIN OUTCOME AND MEASURE: Upper gastrointestinal bleeding, analyzed by a negative binomial model in the intention-to-treat population.
RESULTS: A total of 18 466 patients (median age, 71 years [IQR, 61-79], 13 138 males [71%]) with myocardial infarction were followed up: 9245 during the screening periods and 9221 during the nonscreening periods. At admission, 2284 during the screening periods and 2275 during the nonscreening periods (both 24.7%) reported proton pump inhibitor use. During screening periods, 6480 patients (70%) had undergone testing, of those 1532 (23.6%) tested positive for H pylori. After a median follow-up of 1.9 years, 299 patients in the screening group (incidence rate, 16.8 events per 1000 person-years; cumulative hazard at 3 years, 4.1%) and 336 in the usual care group (incidence rate, 19.2 events per 1000 person-years; cumulative hazard at 3 years, 4.6%) experienced the primary end point of upper gastrointestinal bleeding (rate ratio [RR], 0.90; 95% CI, 0.77-1.05; P = .18). Predefined nonmultiplicity adjusted subgroup analyses showed a heterogeneous intervention effect; for no anemia (RR, 0.98; 95% CI, 0.80-1.21), mild anemia (RR, 0.64; 95% CI, 0.42-0.98), and moderate to severe anemia (RR, 0.44; 95% CI, 0.23-0.87; P for interaction = .03).
CONCLUSIONS AND RELEVANCE: Among unselected patients with acute myocardial infarction, routine H pylori screening did not significantly reduce the risk of upper gastrointestinal bleeding.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05024864.
参考来源
- Hofmann R, James S, Sundqvist MO, et al. Helicobacter pylori Screening After Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI SWEDEHEART Trial. JAMA. 2025. PMID: 40887995. doi:10.1001/jama.2025.15047
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。